📊 LFCR Key Takeaways
Is Lifecore Biomedical, Inc.. de (LFCR) a Good Investment?
LIFECORE is a technically insolvent pharmaceutical company with negative stockholders' equity of -$10.5M, indicating liabilities exceed assets. Despite positive operating cash flow, the company is burning through equity with -$10.0M net losses and -$3.1M operating losses, while carrying a heavy $136M debt burden that it cannot service from operations (negative interest coverage of -0.5x).
Fundamentals are weak: the company is loss-making with a -32% net margin and negative ROA, while operating income does not cover interest expense. The balance sheet carries heavy leverage and negative equity, elevating refinancing and solvency risk despite decent liquidity. Breakeven free cash flow and a 25% gross margin offer some cushion, but sustained margin expansion and deleveraging are needed before the risk profile improves.
Why Buy Lifecore Biomedical, Inc.. de Stock? LFCR Key Strengths
- Positive operating cash flow of $1.8M demonstrates core operations generate cash
- Strong liquidity ratios (current 2.80x, quick 1.67x) provide short-term solvency buffer
- Gross margin of 25% shows underlying business model has structural viability
- Solid liquidity (current and quick ratios) provides near-term cushion
- Positive operating cash flow and roughly breakeven FCF
- Moderate gross margin (25%) indicates some pricing power/cost discipline
LFCR Stock Risks: Lifecore Biomedical, Inc.. de Investment Risks
- Negative stockholders' equity of -$10.5M indicates technical insolvency and distress
- Operating income of -$3.1M and net losses of -$10.0M with -32.1% net margin show unprofitability
- Massive debt burden of $136M with negative interest coverage ratio (-0.5x) creates refinancing risk
- Free cash flow of only $25K with 0.1% FCF margin leaves no financial flexibility for growth or debt service
- Cash runway of ~10 years at current burn rate is inadequate given $136M debt maturity risks
- Negative equity and high long-term debt increase financial risk
- Operating losses with negative interest coverage threaten debt service
- Thin free cash flow limits reinvestment and deleveraging capacity
Key Metrics to Watch
- Path to operating profitability and timeline to positive net income
- Stockholders' equity recovery - current negative equity is unsustainable
- Debt refinancing schedule and ability to service $136M long-term debt
- Operating cash flow sustainability and free cash flow improvement
- Revenue growth and gross margin maintenance in pharmaceutical segment
- Interest coverage
- Free cash flow margin
Lifecore Biomedical, Inc.. de (LFCR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 0.1% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.80x current ratio provides a solid financial cushion.
LFCR Profit Margin, ROE & Profitability Analysis
LFCR vs Healthcare Sector: How Lifecore Biomedical, Inc.. de Compares
How Lifecore Biomedical, Inc.. de compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lifecore Biomedical, Inc.. de Stock Overvalued? LFCR Valuation Analysis 2026
Based on fundamental analysis, Lifecore Biomedical, Inc.. de has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lifecore Biomedical, Inc.. de Balance Sheet: LFCR Debt, Cash & Liquidity
LFCR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lifecore Biomedical, Inc.. de's revenue has declined by 78% over the 5-year period, indicating business contraction. The most recent EPS of $0.33 reflects profitable operations.
LFCR Revenue Growth, EPS Growth & YoY Performance
LFCR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $24.7M | -$10.0M | $-0.29 |
| Q3 2025 | $35.2M | -$14.8M | $0.42 |
| Q2 2025 | $30.2M | $3.5M | $0.10 |
| Q1 2025 | $24.5M | -$10.8M | $-0.35 |
| Q3 2024 | $26.5M | -$10.8M | $0.42 |
| Q2 2024 | $21.9M | $3.5M | $0.10 |
| Q1 2024 | $23.7M | -$10.8M | $-0.35 |
| Q3 2023 | $27.6M | -$9.5M | $-0.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lifecore Biomedical, Inc.. de Dividends, Buybacks & Capital Allocation
LFCR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lifecore Biomedical, Inc.. de (CIK: 0001005286)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LFCR
What is the AI rating for LFCR?
Lifecore Biomedical, Inc.. de (LFCR) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LFCR's key strengths?
Claude: Positive operating cash flow of $1.8M demonstrates core operations generate cash. Strong liquidity ratios (current 2.80x, quick 1.67x) provide short-term solvency buffer. ChatGPT: Solid liquidity (current and quick ratios) provides near-term cushion. Positive operating cash flow and roughly breakeven FCF.
What are the risks of investing in LFCR?
Claude: Negative stockholders' equity of -$10.5M indicates technical insolvency and distress. Operating income of -$3.1M and net losses of -$10.0M with -32.1% net margin show unprofitability. ChatGPT: Negative equity and high long-term debt increase financial risk. Operating losses with negative interest coverage threaten debt service.
What is LFCR's revenue and growth?
Lifecore Biomedical, Inc.. de reported revenue of $31.1M.
Does LFCR pay dividends?
Lifecore Biomedical, Inc.. de does not currently pay dividends.
Where can I find LFCR SEC filings?
Official SEC filings for Lifecore Biomedical, Inc.. de (CIK: 0001005286) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LFCR's EPS?
Lifecore Biomedical, Inc.. de has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LFCR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lifecore Biomedical, Inc.. de has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LFCR stock overvalued or undervalued?
Valuation metrics for LFCR: ROE of N/A (sector avg: 15%), net margin of -32.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LFCR stock in 2026?
Our dual AI analysis gives Lifecore Biomedical, Inc.. de a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LFCR's free cash flow?
Lifecore Biomedical, Inc.. de's operating cash flow is $1.8M, with capital expenditures of $1.7M. FCF margin is 0.1%.
How does LFCR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -32.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.80 (avg: 2).